Simulations Plus Is High-Growth Investment Opportunity In The Wake Of Immunetrics Acquisition: Analyst
Portfolio Pulse from Nabaparna Bhattacharya
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on Simulations Plus (SLP) and raised the price target to $67 from $65, following the acquisition of Immunetrics. The acquisition is expected to strengthen SLP's quantitative systems pharmacology offering and provide immediate synergy and accretion.
June 21, 2023 | 6:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Simulations Plus (SLP) acquires Immunetrics, expected to strengthen its quantitative systems pharmacology offering. Oppenheimer analyst raises price target to $67 and maintains Outperform rating.
The acquisition of Immunetrics is expected to strengthen SLP's offerings in quantitative systems pharmacology, which is a positive development for the company. The Oppenheimer analyst's raised price target and maintained Outperform rating indicate a bullish outlook for SLP's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100